Since the acquisition of the Serotec Group, MorphoSys has been
present in several locations throughout Europe and the USA. The three
primary facilities for the Company include MorphoSys headquarters in
the German biotechnology cluster Martinsried near Munich, newly opened
labs in the academic center of Oxford, England; and offices in the
technology region of Research Triangle Park near Raleigh, North
Carolina, USA.
All activities of MorphoSys’s therapeutic antibody segment are based
in Martinsried. Research activities here include development and
functional characterization of product candidates for the
pharmaceutical and biotechnology industries as well as for the
Company’s internal development pipeline. Additional centralized
functions located in Martinsried are alliance management, responsible
for oversight and service of current collaborations; business
development, which identifies new commercial and academic partnership
opportunities; and the finance and intellectual property departments.
The research antibody segment AbD Serotec is also present in
Martinsried through both administrative functions and generation of new
research antibodies based on the HuCAL technology, related historically
to the Antibodies by Design business initiative.
Martinsried as part of the Munich Biotech Cluster
is the leading biotechnology region in Germany, with approximately 100
biotech companies, including six of the currently 20 public German
biotech companies. One of the contributing factors to the success of
the region is the proximity of the two Munich universities, namely the
Ludwig-Maximilian University and the Munich Technical University, each
with a university clinic, as well as the Max Planck Institutes for
Biochemistry as well as Neurobiology and Psychology and the GSF
National Research Center for Environment and Health.
MorphoSys Headquarters in Martinsried near Munich, Germany
